The American Cancer Society says more people will be diagnosed with cancer this year than ever before. Conventional treatments like surgery, chemotherapy, and radiation are helping to prevent deaths, but can more be done? Emerging research focused on repurposed drugs is proving the answer is YES.
The FLCCC Alliance is proud to announce it has partnered with renowned breast cancer physician and researcher Kathleen Ruddy, MD, to conduct an observational study in collaboration with five U.S. clinics to track patient responses to various adjunct cancer therapies using repurposed drugs. The aim is to determine changes in the five-year survival rate of several types of cancer including breast, prostate, lung, and colorectal.
Study Details
Dr. Marik announces the cancer study partnership with Dr. Ruddy at the Winter 2024 FLCCC Educational Conference.
The final study results will focus on changes in the five-year survival rate of certain cancers and include patients from five clinics nationwide that will collaborate and share de-identified patient information in a protected data collection tool where the data will be tracked and analyzed.
Although the study uses the five-year survival rate after diagnosis as an endpoint, periodic updates of preliminary results will be provided while the study progresses. The study IRB has been officially approved by WCG, which places it in full compliance with all federal guidelines.
The FLCCC Alliance published its Cancer Care Monograph in June 2023. In the FLCCC research partnership with Dr. Ruddy, we hope to build on the already promising results she has documented. It is our mission to bring safe, affordable, and effective cancer treatments to the patients who so desperately need them.
How It Will Work
During the study, participating clinics will collaborate and share de-identified patient information in a protected data collection tool where the data will be tracked and analyzed.
To assist with treatment and data collection, FLCCC has partnered with five clinics operating across the United States. Each clinic participating in the study will work to collaborate with their patients’ respective cancer treatment teams to ensure treatment conforms to patients’ wishes and does not conflict with other treatments.
While there is no cost to enroll in the study, each patient will be responsible for the medical advice and treatment therapies provided by the participating clinics. Costs vary, since each clinic sets its own pricing – some focus on complementary care and work with the patients’ existing oncologists, while others provide end-to-end cancer care including a combination of traditional cancer treatments as well as complementary care using repurposed drugs. Clinic-based therapies are typically more expensive than telemedicine and costs will vary based on each patient’s medical history.
“We hope that our research will bring attention to often overlooked methods for treating cancer as well as managing the symptoms from conventional treatment,” said Paul E. Marik, MD, FCCM, FCCP, lead author of the study, chief scientific officer of the FLCCC and former Chief of Pulmonary and Critical Care Medicine at Eastern Virginia Medical School.
Dr. Ruddy and Dr. Marik will act as lead investigators with Dr. Pierre Kory acting as contributing author. Patients interested in participating in the study should contact these clinics following their contact links listed in the following section below.
Founder, Health and Healing
Lead Investigator, FLCCC Cancer Study
Chief Scientific Officer, FLCCC
Lead Investigator, FLCCC Cancer Study
Chief Medical Officer, FLCCC
Contributing Author, FLCCC Cancer Study
Cancer Study Providers
Founder, Health and Healing
Leading a Better Way Forward
The FLCCC Alliance has been a leader in the investigation of repurposed drugs beyond the prevention and treatment of COVID-19. As a group of highly published, world-renowned critical care physicians and scholars, the FLCCC continues to develop guidance and educational materials on other chronic conditions, including cancer, insulin resistance, long COVID, and post-vaccine syndrome.
“Cancer continues to increase at an alarming rate, especially among younger populations, creating an imminent public health crisis,” said Dr. Ruddy, founder of the New Jersey-based practice Breast Health and Healing. “Over the past 12 months, I have been observing patients with a variety of cancers who have chosen to use repurposed FDA-approved drugs in their treatment, with some having remarkable results. More is to be learned, so I am excited to partner with the FLCCC Alliance on this new research.”
Dr. Marik adds, “Our research is intended to advance a better understanding of how cancer can be treated more efficiently, with fewer side effects, through using well-studied approaches that include readily available medications that are well-studied and known to have minimal side effects.”
It has been our privilege to continue important, life-saving research just like this. These projects are made possible by the generous donations from you: our amazing donors. If you are able, please consider donating to help FLCCC resource this important study today.
About The FLCCC Alliance
The FLCCC Alliance was organized in March 2020 by a group of highly published, world renowned critical care physicians and scholars with the academic support of allied physicians from around the world. FLCCC’s goal is to research and develop lifesaving protocols for the prevention and treatment of COVID-19 in all stages of illness including the I-RECOVER protocols for Long COVID and Post Vaccine Syndrome.
